BMS: System needs to do better

"BMS acknowledge the progress made in rare cancers through MRFF grants and budget announcements for rare diseases (including cancers). However, we challenge that average approval listing delay of 320 days is not good enough and believe we all need to strive to do better," said the company in a statement. …